Skip to content

Evaluating the Impact of Incentives on Clinical Trial Participation

Evaluating the Impact of Incentives on HIV Related Clinical Trial Participation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04809636
Enrollment
360
Registered
2021-03-22
Start date
2021-01-01
Completion date
2022-12-31
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Hiv, Incentives

Keywords

hiv, aging, incentives

Brief summary

The objective of this study is to investigate the impact of incentives on clinical trial participation. 1) characterize key stakeholders' views on and assessment of incentives, 2) reach consensus among stakeholders on the factors to be considered when choosing incentives and their relative importance, 3) pilot test using vignettes for incentive decision making. We hypothesize that potential study participants make trade-offs regarding the characteristics of a research study when deciding whether to volunteer. This amendment is to document IRB reliance between UCR and USF.

Interventions

While this is not an intervention, there will be separate participants for the survey study and for the other components of the study (focus groups, interviews, conjoint analysis, piloting the vignettes

Sponsors

University of South Florida
CollaboratorOTHER
University of California, Riverside
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* people living with HIV * biomedical HIV researchers * IRB members/bioethicists involved in HIV research

Exclusion criteria

* people under 18 years of age * people living outside of the United States * people who do not speak English

Design outcomes

Primary

MeasureTime frameDescription
characterize how people living with HIV assess incentives3 monthswe will conduct a 20 question quantitative survey of a nationally representative sample of people living with HIV asking about specific study payment information and scenarios
characterize key stakeholders' views on and assessment of incentives3 monthsfocus groups, and key informant interviews will be used to characterize key stakeholders' (people aging with HIV, IRB members, researchers) views on and assessment of incentives, with qualitative analysis of text done using RaDAR. We will use Conjoint Analysis (CJA) to estimate the relative importance (also called weight) that participants place on each study characteristic when choosing between different hypothetical studies.
pilot testing vignettes for incentive decision making3 monthsWe will develop HIV related vignettes (hypothetical scenarios) utilizing the data from outcomes 1 and 2. Specifically, once we have 6 to 8 study characteristics from Aim 2, and the final number of choices (2 - 3) per characteristic, we will use a factorial design to create 25 vignettes (hypothetical scenarios). Individuals from each group (i.e., study participants, researchers, and IRB members) will select the most appropriate incentive from a list of possibilities based on various scenarios. These vignettes will be based on studies identified in the literature and a review of consent forms and created in conjunction with the external advisory board (including pre-testing and revision prior to finalization).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026